The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant chemotherapy (ACT) in stage II colon cancer (CC) in patients with Lynch syndrome.
Karsten Schulmann
Honoraria - Amgen; AstraZeneca; Falk Pharmaceuticals; Merck Serono
Other Remuneration - Merck Serono; Novartis; Pfizer; Roche
Sven Koepnick
No relevant relationships to disclose
Christoph Engel
No relevant relationships to disclose
Christiane Bernhardt
No relevant relationships to disclose
Verena Steinke
No relevant relationships to disclose
Brigitte Royer-Pokora
No relevant relationships to disclose
Hans K. Schackert
No relevant relationships to disclose
Magnus von Knebel Doeberitz
No relevant relationships to disclose
Elke Holinski-Feder
No relevant relationships to disclose
Reinhard B├╝ttner
No relevant relationships to disclose
Wolff H. Schmiegel
Consultant or Advisory Role - Amgen; AstraZeneca; Merck; Roche
Honoraria - Abbott Laboratories; Amgen; AstraZeneca; Falk Pharmaceuticals; Merck; Pfizer; Roche
Research Funding - Pfizer; Roche; Sanofi
Other Remuneration - AstraZeneca; Merck; Roche